PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies

The use of PARP inhibitors (PARPi) in patients with epithelial ovarian cancer is expanding, with the transition from use in recurrent disease to the first-line setting. This is accompanied with an increasing population of patients who develop acquired PARPi resistance. Coupled with those patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Rowan E, El-Shakankery, Karim H, Lee, Jung-Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024188/
https://www.ncbi.nlm.nih.gov/pubmed/35320891
http://dx.doi.org/10.3802/jgo.2022.33.e44

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024188/
https://www.ncbi.nlm.nih.gov/pubmed/35320891
http://dx.doi.org/10.3802/jgo.2022.33.e44

Ejemplares similares